CN117500828A - 结合VEGF和Ang2的双特异性结合分子以及其用途 - Google Patents

结合VEGF和Ang2的双特异性结合分子以及其用途 Download PDF

Info

Publication number
CN117500828A
CN117500828A CN202280039743.2A CN202280039743A CN117500828A CN 117500828 A CN117500828 A CN 117500828A CN 202280039743 A CN202280039743 A CN 202280039743A CN 117500828 A CN117500828 A CN 117500828A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
vegf
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039743.2A
Other languages
English (en)
Chinese (zh)
Inventor
黎一鸣
胡思怡
荆华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of CN117500828A publication Critical patent/CN117500828A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280039743.2A 2021-06-04 2022-06-02 结合VEGF和Ang2的双特异性结合分子以及其用途 Pending CN117500828A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021106237792 2021-06-04
CN202110623779 2021-06-04
PCT/CN2022/096848 WO2022253314A1 (zh) 2021-06-04 2022-06-02 结合VEGF和Ang2的双特异性结合分子以及其用途

Publications (1)

Publication Number Publication Date
CN117500828A true CN117500828A (zh) 2024-02-02

Family

ID=84323888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039743.2A Pending CN117500828A (zh) 2021-06-04 2022-06-02 结合VEGF和Ang2的双特异性结合分子以及其用途

Country Status (11)

Country Link
US (1) US20240247057A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349861A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520693A (cg-RX-API-DMAC7.html)
KR (1) KR20240023095A (cg-RX-API-DMAC7.html)
CN (1) CN117500828A (cg-RX-API-DMAC7.html)
AU (1) AU2022287100A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221192A1 (cg-RX-API-DMAC7.html)
IL (1) IL309035A (cg-RX-API-DMAC7.html)
MX (1) MX2023014407A (cg-RX-API-DMAC7.html)
TW (1) TW202302633A (cg-RX-API-DMAC7.html)
WO (1) WO2022253314A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400512A4 (en) * 2021-09-10 2025-07-23 Soter Biopharma Pte Ltd ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE
AU2023404529A1 (en) * 2022-12-01 2025-07-10 Innovent Biologics (Suzhou) Co., Ltd. Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof
AU2025207813A1 (en) * 2024-01-12 2026-07-23 Novelty Nobility Inc. Bispecific antibody specifically binding to c-kit and vegf, and use thereof
TW202604956A (zh) * 2024-04-29 2026-02-01 大陸商深圳歐科健生物醫藥科技有限公司 Ang2/vegf 雙特異性結合分子
WO2026037351A1 (zh) * 2024-08-13 2026-02-19 长春金赛药业有限责任公司 同时结合vegf及ang-2的融合蛋白及其用途
CN121517578A (zh) * 2024-08-13 2026-02-13 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
JP2017537896A (ja) * 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2

Also Published As

Publication number Publication date
TW202302633A (zh) 2023-01-16
JP2024520693A (ja) 2024-05-24
MX2023014407A (es) 2024-04-23
EP4349861A4 (en) 2025-07-23
IL309035A (en) 2024-02-01
AU2022287100A1 (en) 2024-01-25
US20240247057A1 (en) 2024-07-25
KR20240023095A (ko) 2024-02-20
EP4349861A1 (en) 2024-04-10
WO2022253314A1 (zh) 2022-12-08
CA3221192A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
EP4349861A1 (en) Bispecific binding molecule binding vegf and ang2 and use thereof
JP7097364B2 (ja) グレムリン-1の結晶構造及び阻害抗体
US20190202904A1 (en) Synthetic antibodies against vegf and their uses
KR20210141992A (ko) Vegf 및 ang2에 특이적으로 결합되는 이중특이적 항체
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
JP2024518724A (ja) 抗masp2抗体、その抗原結合断片および医薬用途
CN120302997A (zh) 包含结合VEGF和Ang2的双特异性结合分子的制剂以及其用途
CA3208368A1 (en) Vegfa-binding molecules
JP2024529119A (ja) 抗vegfaとvegfc二重特異性抗体およびその使用
KR20230045095A (ko) Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자
JP7804295B2 (ja) 二機能性融合タンパク質およびその用途
WO2021175191A1 (zh) 抗tim-3抗体及其用途
WO2024188179A1 (zh) 一种靶向ctgf的抗体或其抗原结合片段及其应用
WO2025119329A1 (zh) 抗c5和htra1双特异性抗体及其用途
HK40104627A (en) Bi-functional fusion protein and uses thereof
JP2024506664A (ja) 抗vegf抗体およびその使用
TW202334214A (zh) 抗il-17/vegf雙功能融合蛋白及其用途
KR20200089699A (ko) 비알콜성 지방간염의 항-huTNFR1 요법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105372

Country of ref document: HK